[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) — Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.
(A+PerfusC™ 3D System-a perfusion-based 3D cell culture in a compact incubator)
The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real‑time observation. The system supports up to 12 days of continuous, hands‑free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by:
- 8 independent channel/patient source per plate
- 600 tumor spheroids per row for one patient
- 4,800 tumor spheroids per plate
- Easy to transfer into 96 or 384 well plate for high-throughput drug screening
- Easy to mount on microscopy platforms
- Expandable- control platform supporting up to four incubators. (undergoing)
A+PerfusC™ system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established.
Potential applications include personalized oncology research, invitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global 3D cell culture market was valued at USD 2.32 billion in 2025 and is projected to exceed USD 4.71 billion by 2030, representing a compound annual growth rate of over 15.6% (source: https://www.mordorintelligence.com/industry-reports/3d-cell-culture-market).
Dr. Yi Lu, CEO of the Company, commented: “Traditional static cell culture often leads to uneven nutrient delivery and waste buildup, compromising cell growth, viability, and reproducibility. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste can rapidly accumulate inside the micro-grooves, requiring more frequent medium replacement which can be labor-intensive to preserve culture quality.”
“Our 3D culture system evenly delivers nutrients and clears waste, reducing cellular stress, boosting long-term viability, and more accurately mimicking human tissue complexity for improved drug response and disease modeling.”
“The Company plans to scale up the A+PerfusC™ system for high‑throughput use and integrate imaging with AI‑driven analytics, aiming to accelerate tumor profiling, refine cell therapy protocols, and advance personalized treatment development.”